NEW YORK, New York — November 5, 2025 — Leads & Copy — MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its third quarter 2025 financial results before the market opens on Friday, November 14th, followed by a conference call and webcast at 8:30 a.m. ET to discuss the results, recent clinical progress including SITC data, and upcoming corporate milestones.
The announcement follows MiNK’s late-breaking presentation at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where new clinical data from the company’s agenT-797 iNKT cell therapy demonstrated durable immune reconstitution and signals of activity in patients with advanced solid tumors.
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website following the event. Live event link: https://edge.media-server.com/mmc/p/4bufw45x
Webcast Replay: https://investor.minktherapeutics.com/events-and-presentations
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses.
Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure.
Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com
Source: MiNK Therapeutics
